-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $166

Benzinga·04/07/2026 12:45:10
Listen to the news
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $151 to $166.